Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

An Open-label, Multiple Dose Study to Assess the Steady-state Skin Concentrations and Pharmacokinetics of Vildagliptin 50 mg BID for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

This study will look at the skin accumulation of vildagliptin and its two major metabolites, LAY151 and LAF237-O-Glucuronide, after vildagliptin 50 mg given orally twice a day for 10 days in both healthy volunteers and patients with type 2 diabetes.

Inclusion Criteria:

• Healthy volunteers and patients with type 2 diabetes
• Non-smoking, Caucasian and African American, male and female (postmenopausal, surgically sterile or using double-barrier method of contraception) subjects between 30 and 65 years of age (inclusive)
• Type 2 diabetics on metformin and/or sufonylurea

Exclusion Criteria:

• History of type 1 diabetes or insulin use
• History of coagulation abnormalities
• History of abnormal heart conditions
• Pregnancy or breastfeeding

Other protocol-defined inclusion/exclusion criteria may apply